Navigation Links
DATATRAK Awarded First Study With Kreara Solutions
Date:3/8/2011

CLEVELAND, March 8, 2011 /PRNewswire/-- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that it has been awarded its first study by Kreara Solutions, a Contract Research Organization (CRO) in India, with which the Company had partnered in 2010. Both companies will work together in order to execute a Phase II study for the Dermatology Division of a Global Enterprise, whose core competencies include the fields of Health Care, Nutrition and High-Tech Materials.  

The trial will be conducted in Japan and employ several CROs based in Japan, India and the USA to conduct project management, monitoring, data management and other study-specific services. All of the CROs, as well as the Sponsor, will be utilizing DATATRAK eClinical™ for Electronic Data Capture (EDC) and Medical Coding.

Anoop P. Ambika, Kreara's CEO and Managing Director said, "Kreara has always strived to provide quality and timely data management services to its clients in adherence to the internal standards and standards set by the client and regulatory bodies. Kreara looks forward to working closely with DATATRAK to deliver the challenging requirements of this trial, all the while adhering to the cost, quality and timeliness as envisioned during the planning phase."

"DATATRAK's unified eClinical platform is an ideal solution for studies which intend to employ multiple CROs from various geographic locations around the world," said Laurence P. Birch, DATATRAK's Chairman and CEO.  "We can help companies to streamline their study communications, provide a single point of access for all study users, and enable both the Sponsor and CROs to gain real-time access to patient data. We are excited to embark on this first study with Kreara, especially as we guide them through the design and deployment of their study as an Enterprise Transfer client."

About Kreara Solutions

KREARA Solutions is a clinical data management and biometrics solution provider based out of the beautiful campus of Technopark Trivandrum, Kerala in India. Kreara was established in April 2004 as a private limited company with the intention of providing quality services for the clinical research, life sciences and financial markets. Kreara has grown into a leading Clinical Research Organization that specializes in providing data management, statistical and software solutions for the process of clinical drug development. Having grown into one of the most trusted partners for some of the life sciences companies across the globe, Kreara has worked with clients from Europe, USA and Japan. For more information on Kreara, please visit http://www.kreara.com.

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, has successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 67 countries. DATATRAK has offices located in Cleveland, Ohio, and Bryan, Texas. For more information, visit http://www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's quarterly report filed with the Pink OTC Markets on November 12, 2010 announcing its results for the three-month period ending September 30, 2010. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE DATATRAK International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0
2. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
3. DATATRAK International Reports First Quarter Results for 2008
4. European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK
5. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
6. DATATRAK eClinical(TM) Supports Multifaceted Studies
7. DATATRAK to Present at 2009 SCDM Annual Conference
8. DATATRAK Signs 6 Year Study with New Device Client
9. DATATRAK Attends 13th Annual DIA Workshop in Japan for Clinical Data Management
10. DATATRAK International, Inc. Announces Year-End Backlog
11. DATATRAK Signs Five-Year Registry Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... Research and Markets has announced the addition of ...  report to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Emission Tomography (PET) scanner and cyclotron install base in ... the current known number of PET scanners and cyclotrons ... also contains a detailed breakdown of this equipment by ...
(Date:5/5/2016)... 5, 2016 ... of the  "Europe Thrombocythemia Market and ... to their offering.       ... ,The latest research Europe Thrombocythemia Market ... provides comprehensive insights into Thrombocythemia pipeline ...
(Date:5/5/2016)... 5, 2016 Research ... "Europe Thalassaemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights - 2016, provides ... epidemiology, Thalassaemia market valuations and forecast, Thalassaemia ...
Breaking Medicine Technology:
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... ... an online provider of career-focused education and corporate training, and the National Military ... pleased to announce Maritza Aquino as the second full-tuition scholarship recipient of 2016. ...
(Date:5/5/2016)... ... ... TransWipe Volume 3 is a set of 30 professional transition animations created ... two video clips to instantly add a unique transition to any Final Cut Pro ... orientation options. TransWipe Volume 3 is a Final Cut Pro X exclusive plugin. , ...
(Date:5/5/2016)... ... 2016 , ... The U.S. Food and Drug Administration today ... submit their products through an arduous federal approval process. The rules, which treat ... market since February 15, 2007. That would essentially ban 99 percent of all ...
(Date:5/5/2016)... ... 2016 , ... Spring Fertility , the only fertility ... egg freezing, today announced the grand opening of its first location in San ... Fertility offers both fertility preservation (egg, sperm, embryo, and testicular and ovarian tissue ...
(Date:5/5/2016)... ... ... Derrin Doty Group has unveiled the latest charity campaign in their ongoing community ... The insurance provider’s caring team has been so moved by the sudden death of ... the flu, that they have decided to extend their original campaign. Compassionate community members ...
Breaking Medicine News(10 mins):